Drug Profile
Research programme: ZW 9 - Zymeworks
Alternative Names: Research programme: ZW-9 - ZymeworksLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Zymeworks
- Class Bispecific antibodies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Breast-cancer in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in Canada
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastric-cancer in Canada